Skip to main content
Dermapharm Holding SE logo

Dermapharm Holding SE — Investor Relations & Filings

Ticker · DMP ISIN · DE000A2GS5D8 LEI · 5299009F0KNZINQQQK37 F Manufacturing
Open in API
Filings indexed 245 across all filing types
Latest filing 2025-05-16 AGM Information
Country DE Germany
Listing F DMP

About Dermapharm Holding SE

https://ir.dermapharm.de/index-EN.php

Dermapharm Holding SE is a manufacturer of branded pharmaceuticals and healthcare products, with a focus on the patent-free segment. The company operates an integrated business model that encompasses the entire value chain, including in-house research and development, production, and distribution. A dedicated pharmaceutical sales force manages the marketing and sales of its brand products. Dermapharm maintains a diversified portfolio concentrated on selected therapeutic areas, allowing it to establish strong market positions. The company operates several production, development, and distribution sites to support its operations and international expansion.

Recent filings

Filing Released Lang Actions
Dermapharm Holding SE: Bekanntmachung der Einberufung zur Hauptversammlung am 26.06.2025 in Niederpocking mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 100% confidence The document is explicitly titled 'Bekanntmachung der Einberufung zur Hauptversammlung' (Announcement of the Convocation to the General Meeting) and contains an 'Einladung zur ordentlichen Hauptversammlung 2025' (Invitation to the Ordinary General Meeting 2025). It details the agenda (Tagesordnung) for the meeting scheduled for June 26, 2025, including proposals for dividend approval, discharge of management/supervisory boards, and auditor elections. This content directly relates to the formal notice and materials for an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document length is substantial (over 36k characters), indicating it is the full notice, not just a brief announcement of publication (RPA).
2025-05-16 German
Dermapharm Holding SE performs in line with projections in Q1 2025, confirms full-year guidance
Earnings Release Classification · 100% confidence The document explicitly states it 'publishes its results for the first three months of 2025' and provides detailed segment performance figures (revenue, adjusted EBITDA) for Q1 2025. The keywords used are 'Quarterly / Interim Statement' and the content is a comprehensive summary of financial performance for a period shorter than a year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of a report (RPA) because it contains the full results, not just a notice that the report is available. Q1 2025
2025-05-15 English
Q1 statement / Q1 financial report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM STATEMENT Q1 2025' and contains comprehensive financial data, including a consolidated statement of financial position, a consolidated statement of comprehensive income, and detailed segment performance analysis for the first quarter of 2025. It is not an announcement of a report, but the report itself, containing substantive financial statements and analysis, which fits the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-15 English
Report Publication Announcement 2025
Report Publication Announcement Classification · 100% confidence The document is titled "Dermapharm Holding SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements." It explicitly states that it is a preliminary announcement regarding the disclosure of financial statements (Quarterly/Interim statement) scheduled for a future date (May 15, 2025). According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a report, rather than containing the report itself, should be classified as a Report Publication Announcement (RPA). The document length is very short (1985 characters), confirming it is an announcement, not the full financial report (IR or ER).
2025-05-07 English
Declaration of Voting Results & Voting Rights Announcements 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Notification of Major Holdings' and explicitly references 'Voting rights Announcements' and compliance with Article 40, Section 1 of the WpHG (German Securities Trading Act). It details changes in the percentage of voting rights held by an entity ('Mawer Global Small Cap Fund') in the issuer ('Dermapharm Holding SE'), crossing or reaching a threshold. This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership levels.
2025-04-14 English
Dermapharm Holding SE: Susanne Gertrud Pia Lanz, buy
Director's Dealing Classification · 100% confidence The document explicitly contains the header "Directors’ Dealings" and details transactions by a person discharging managerial responsibilities (Susanne Gertrud Pia Lanz) and a person closely associated with her (Lothar Lanz). This directly matches the definition for Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document structure and content confirm this classification.
2025-04-08 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.